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IL-17A and IL-17F are cytokines that induce 
multiple proinfl  ammatory mediators, includ-
ing chemokines, cytokines, and metallopro-
teinases, from epithelial and fi  broblast  cells 
(1). Both IL-17A and IL-17F are produced by 
Th17 cells, a distinct lineage of CD4+ eff  ector 
cells (2–8). Th17 cell diff  erentiation is initi-
ated by TGF-β signaling in the context of 
proinfl  ammatory cytokines, particularly IL-6 
as well as IL-1β and TNF-α. Maintenance 
and survival of Th17 cells, in contrast, are de-
pendent on IL-23. In vivo studies in murine 
disease and infection models indicate that the 
Th17 lineage plays a pathogenic role in auto-
immune disease and a protective role in im-
munosurveillance (3, 5, 7–11).
We sought to identify other ILs that are 
produced by Th17 cells. We demonstrate that 
IL-22, an IL-10 family member, was preferen-
tially expressed by this T cell lineage. IL-22 
acts directly on epithelial and some fi  broblast 
cells in peripheral tissues and induces an acute 
phase response in vivo and chemokines and 
metalloproteinases in vitro (12–16). We show 
that IL-22 acted cooperatively with IL-17A or 
IL-17F to enhance expression of antimicrobial 
peptides   associated with host defense. Our data 
reveal IL-22 as an eff   ector cytokine of the 
Th17 lineage.
RESULTS AND DISCUSSION
IL-22 transcript is more highly expressed 
in Th17 cells than Th1 or Th2
To identify potential Th17 cytokines, we dif-
ferentiated naive (CD62LhiCD4+) T cells puri-
fi  ed from DO11.10 (DO11) mice to the Th1 
(IL-12 and anti–IL-4), Th2 (IL-4 and anti–
IFN-γ), and Th17 (TGF-β, IL-6, IL-1β, 
TNF-α, IL-23, anti–IFN-γ, and anti–IL-4) 
lineages for 7 d. We then examined the ex-
pression of cytokine transcripts by quantitative 
PCR after restimulation of T cells with PMA 
and ionomycin. Th1 cells expressed the high-
est amounts of IFN-γ transcript, Th2 cells had 
the highest abundance of IL-4, and Th17 cells 
produced the greatest abundance of IL-17A 
and IL-17F, demonstrating that these cells 
were successfully diff  erentiated (Fig. 1 A). Of 
22 additional ILs examined, IL-22 transcript 
expression was higher in Th17 cells relative to 
Interleukin (IL)-22 and IL-17 are coexpressed 
by Th17 cells and cooperatively enhance 
expression of antimicrobial peptides
Spencer C. Liang,1 Xiang-Yang Tan,2 Deborah P. Luxenberg,1 
Riyez Karim,2 Kyriaki Dunussi-Joannopoulos,1 Mary Collins,1 
and Lynette A. Fouser1
1Infl  ammation and 2Antibody Technologies Group, Wyeth Research, Cambridge, MA 02140
Th17 cells are a distinct lineage of effector CD4+ T cells characterized by their production 
of interleukin (IL)-17. We demonstrate that Th17 cells also expressed IL-22, an IL-10 
family member, at substantially higher amounts than T helper (Th)1 or Th2 cells. Similar to 
IL-17A, IL-22 expression was initiated by transforming growth factor 𝗃 signaling in the 
context of IL-6 and other proinfl  ammatory cytokines. The subsequent expansion of IL-22–
producing cells was dependent on IL-23. We further demonstrate that IL-22 was coex-
pressed in vitro and in vivo with both IL-17A and IL-17F. To study a functional relationship 
among these cytokines, we examined the expression of antimicrobial peptides by primary 
keratinocytes treated with combinations of IL-22, IL-17A, and IL-17F. IL-22 in conjunction 
with IL-17A or IL-17F synergistically induced the expression of 𝗃-defensin 2 and S100A9 
and additively enhanced the expression of S100A7 and S100A8. Collectively, we have 
identifi  ed IL-22 as a new cytokine expressed by Th17 cells that synergizes with IL-17A or 
IL-17F to regulate genes associated with skin innate immunity.
CORRESPONDENCE
Lynette A. Fouser: 
lfouser@wyeth.com
The online version of this article contains supplemental material.2272  IL-22 IS A TH17 CYTOKINE | Liang et al. 
Th1 by 120-fold or Th2 by 700-fold (Fig. 1 B). In contrast, 
expression of IL-2, IL-3, IL-5, IL-6, IL-9, IL-10, IL-13, IL- 
21, IL-24, IL-25, and IL-31 transcript was equivalent 
or more abundant in Th1 or Th2 cells relative to Th17 (Fig. 
1 C). Non–T cell–derived cytokines, including IL-1, IL-7, 
IL-11, IL-15, IL-16, IL-18, IL-19, IL-20, IL-27, and IL-28, 
were not expressed highly in any of the T cell lineages 
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20061308/DC1). In summary, IL-22 was expressed at 
higher amounts by Th17 cells than by Th1 or Th2.
Th17 cells are the main producers of IL-22
IL-22 is a member of the IL-10 family, along with IL-10, IL-
19, IL-20, IL-24, and IL-26 (16). Activation of human CD4+ 
T cells with IL-12 and anti–IL-4 enhances IL-22 transcript 
expression, suggesting that IL-22 is a Th1 cytokine (17). 
However, the expression of IL-22 protein from T cells has 
not been reported. To study this, we generated monoclonal 
antibodies to murine IL-22. Naive DO11 T cells activated 
with irradiated splenocytes and OVA323–339 (OVAp) (Th0) 
produced minimal amounts of IL-22 (<100 pg/ml) as deter-
mined by ELISA (Fig. 2 A). Although IL-22 expression was 
enhanced during Th1 (110-fold) and Th2 (40-fold) diff  eren-
tiation as compared with Th0, activation with IL-17–inducing 
conditions resulted in an even greater increase in IL-22 
  production. TGF-β, IL-6, IL-1β, and TNF-α enhanced 
IL-22 expression by 360-fold, whereas activation with IL-23, 
anti–IFN-γ, and anti–IL-4 increased IL-22 production 
by 460-fold. A combination of these conditions (Th17) 
yielded the greatest expression of IL-22, 2,400-fold over 
Th0 and 22-fold higher than Th1. These data demon-
strate that IL-22 protein is expressed most abundantly during 
Th17 diff  erentiation.
Because some IL-22 was induced under Th1 and Th2 
conditions during primary T cell activation, we examined 
whether a secondary stimulation of these cells could enhance 
IL-22 production. Naive DO11 T cells were activated for 7 d 
with Th1, Th2, and Th17 conditions, or with TGF-β, IL-6, 
IL-1β, and TNF-α. Upon restimulation with just OVAp, 
IL-2, and irradiated splenocytes, cells originally diff  erentiated 
with TGF-β, IL-6, IL-1β, and TNF-α or with Th17 condi-
tions produced at least fi  vefold more IL-22 than Th1 or Th2 
cells (Fig. 2 B). The continued diff  erentiation of Th17 cells 
along the Th17 lineage by restimulating in the presence of 
IL-23, anti–IFN-γ, and anti–IL-4 enhanced IL-22 produc-
tion by at least 12-fold over restimulation of cells with OVAp 
alone or with IL-12, anti–IL-4. In contrast, IL-22 production 
was not enhanced by restimulation of Th1 cells with IL-12, 
Figure 1.  IL-22 transcript expression is high in Th17 cells. Purifi  ed 
CD62LhiCD4+ (naive) DO11 T cells were activated with irradiated splenocytes, 
OVA323–339 (OVAp), and various cytokines and antibodies to differentiate cells 
to Th1 (IL-12, anti–IL-4), Th2 (IL-4, anti–IFN-γ), and Th17 (TGF-β, IL-6, IL-1β, 
TNF-α, IL-23, anti–IFN-γ, anti–IL-4) lineages. On day 7 of culture, CD4
+ T cells 
were repurifi  ed and rested overnight. Cells were then restimulated with PMA 
and ionomycin under differentiation conditions for 6 h. RNA was prepared 
and quantitative PCR was performed in A to ensure that cells were properly 
differentiated. (B and C) ILs known to be expressed in T cells were evaluated 
by quantitative PCR. All transcript amounts were normalized to HPRT, and 
fold induction was calculated relative to unactivated, naive DO11 T cells. Data 
shown are representative of two independent experiments. Error bars are SD.JEM VOL. 203, October 2, 2006  2273
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anti–IL-4 or of Th2 cells with IL-4, anti–IFN-γ. These 
  results show that further diff  erentiation toward Th1 or Th2 
does not enhance IL-22 production. In addition, restimula-
tion of Th1 and Th2 cells with IL-23, anti–IFN-γ, and anti–
IL-4 did not enhance IL-22 production to that observed with 
Th17 cells activated under the same condition. These data 
demonstrate that IL-23 is more potent than IL-12 in stimu-
lating IL-22 expression and that Th17 cells are the major pro-
ducers of IL-22.
We also examined whether IL-22 could modulate prolif-
eration or IFN-γ, IL-4, and IL-17A production from 
naive, Th1, Th2, and Th17 cells. We did not observe any 
changes when T cells were treated with exogenous IL-22 
(Fig. S2, available at http://www.jem.org/cgi/content/full/
jem.20061308/DC1). The transcript for the high affi   nity 
  receptor subunit, IL-22R1, was not detected in any T cell 
population. IL-17A or IL-17F also did not induce IL-22 ex-
pression from naive, Th1, Th2, or Th17 cells (not depicted). 
These results demonstrate that IL-22 and IL-17A/IL-17F 
do not modulate each other’s expression by CD4+ T cells.
We next performed intracellular cytokine staining to 
  determine if IL-22 can be coexpressed with IL-17A. Cells 
activated under Th0, Th1, or Th2 conditions had minimal 
expansion of IL-22+ cells (≤0.2%; Fig. 2 C). Activation 
  under Th17 conditions generated a substantial population 
of IL-22–expressing cells (8.7%), with 81% of IL-22+ cells 
Figure 2.  Th17 cells express IL-22 protein. (A) Naive DO11 T cells 
were activated with irradiated splenocytes, OVAp, and various cytokines 
and antibodies. IL-22, IL-17A, and IFN-γ concentrations were measured 
on day 5. (B) Naive DO11 cells were differentiated under Th1, Th2, or Th17 
conditions, or with TGF-β, IL-6, IL-1β, and TNF-α for 7 d. After resting 
overnight, cells were then restimulated with OVAp, IL-2, irradiated spleno-
cytes, and combinations of cytokines and antibodies. IL-22 and IL-17A 
concentrations were measured on day 5. (C) Intracellular cytokine staining 
was performed on cells from A on day 5. Plots are gated on KJ126+CD4+ 
cells. (D) Naive DO11 T cells were activated as in A with the indicated cyto-
kines. Intracellular cytokine staining was performed on day 5. Data shown 
are representative of three independent experiments. Error bars are SD.2274  IL-22 IS A TH17 CYTOKINE | Liang et al. 
expressing IL-17A and only 1% expressing IFN-γ. We fur-
ther examined the roles of individual cytokines under Th17 
diff  erentiation conditions. Only 0.2% of cells activated with 
exogenous TGF-β expressed IL-22 (Fig. 2 D). Activation 
with IL-6, IL-1β, and TNF-α enhanced IL-22+ cells (1.9%). 
The use of a neutralizing antibody to TGF-β indicated that 
endogenous TGF-β is important for optimal expression 
of IL-22 induced by IL-6, IL-1β, and TNF-α (Fig. S3, avail-
able at http://www.jem.org/cgi/content/full/jem.20061308/
DC1). The addition of exogenous TGF-β to IL-6, IL-1β, 
and TNF-α further increased IL-22+ cells (2.8%), with 
62% of IL-22+ cells expressing IL-17A or IL-17F (Fig. 2 D). 
Figure 3.  IL-23 expands IL-22–producing cells. CFSE-labeled naive 
DO11 T cells were activated with OVAp, irradiated splenocytes, TGF-β, and 
IL-6. TNF-α, IL-1β, IL-23, or IL-12 was added to some cultures. Intracellu-
lar cytokine staining for IL-22 and IL-17A was performed on days 1–5. 
(A) Percentages of IL-22+ cells on day 1–5 and representative plots on 
days 2 and 4 are shown. (B) CFSE profi  les on day 4 of cells separated into 
four populations: IL-22+IL-17A−, IL-22+IL-17A+, IL-22−IL-17A+, and 
IL-22−IL-17A−. Percentage of cells in each peak is shown. (C) Naive DO11 
T cells were cultured with LPS-activated DCs, OVAp, and neutralizing anti-
bodies to IL-23R, IL-12p40, or respective isotype controls. IL-22 concen-
trations were determined on day 5. Data are representative of at least 
two experiments.JEM VOL. 203, October 2, 2006  2275
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Activation with IL-23, along with TGF-β, IL-6, IL-1β, and 
TNF-α, led to a threefold increase in IL-22+ cells (9.5%). 
80% of IL-22+ cells produced either IL-17A or IL-17F, with 
44% expressing both IL-17A and IL-17F. In summary, these 
data demonstrate that IL-22 protein is produced at greater 
amounts by Th17 cells and that IL-22 is coexpressed with 
both IL-17A and IL-17F during Th17 diff  erentiation.
IL-23 enhances the expansion of IL-22–producing cells 
during Th17 differentiation
To further examine how IL-23 enhances IL-22 expression, 
we diff  erentiated CFSE-labeled naive DO11 T cells to Th17 
with various cytokines and analyzed the expression of IL-22 
from days 1 to 5 of culture. Cells activated with only TGF-β 
and IL-6 peaked in IL-22 (14%) expression on day 2 and 
  decreased substantially by day 3 (Fig. 3 A). Neither TNF-α, 
IL-1β, nor IL-12 addition prevented the decrease in expres-
sion of IL-22 observed after day 2. In contrast, cells activated 
with IL-23 as well as TGF-β and IL-6 expressed at least fi  ve-
fold more IL-22 on day 4. To examine if IL-23 was inducing 
the expansion of IL-22–producing cells, we analyzed the 
CFSE dilution profi  les of cells expressing IL-22 and/or IL-
17A on day 4 (Fig. 3 B). We did not observe any diff  erences 
in CFSE between IL-22−IL-17A+ and IL-22−IL-17A− cells 
activated with TGF-β and IL-6 alone or when supplemented 
with TNF-α, IL-1β, or IL-23. This suggests that there is no 
correlation between IL-17A expression and proliferation. 
When we examined the CFSE profi  les of IL-22+IL-17A− 
and IL-22+IL-17A+ cells activated with TGF-β and IL-6, we 
observed that these cells had proliferated less than IL-22−
IL-17A− and IL-22−IL-17A+ cells. Similar fi  ndings  were 
  observed in cultures supplemented with IL-1β, TNF-α, or 
IL-12 (Fig. 3 B and not depicted). In contrast, IL-23 in the 
context of TGF-β and IL-6 enhanced the proliferation and 
expansion of IL-22+IL-17A− and IL-22+IL-17A+ cells (Fig. 
3 B). These fi   ndings demonstrate that IL-23 drives the 
  expansion of IL-22–producing cells in the Th17 lineage.
To examine if endogenous IL-23 is necessary for optimal 
IL-22 expression, we activated naive DO11 T cells with 
LPS-treated DCs in the presence of anti–IL-23R to block 
Figure 4.  IL-22 is coexpressed with IL-17A and IL-17F in vivo. 
C57BL/6 mice were immunized with 100 μg OVA emulsifi  ed in CFA. 7 d 
after immunization, popliteal LN cells were harvested and the intracellular 
cytokine staining protocol was immediately performed. (A) LN cells were 
stained for CD4 and IL-22, IL-17A, and IL-17F. (B) IL-22 expression was 
analyzed in relation to IL-17A, IL-17F, IFN-γ, IL-4, and IL-10 in CD4+ 
T cells. (C) Expression of IL-22 in IL-17A+ and/or IL-17F+ populations was 
analyzed. (D) Expression of IL-17A and IL-17F in IL-22
+ cells was deter-
mined. (E) LN cells were restimulated with 200 μg/ml OVA. IL-12 or IL-23 
was added as indicated. IL-22 and IL-17A concentrations were examined 
on day 4. Data shown are representative of three independent experi-
ments. Error bars are SD.2276  IL-22 IS A TH17 CYTOKINE | Liang et al. 
IL-23 signaling or anti–IL-12p40 to neutralize both IL-12 
and IL-23. Neutralization of IL-23R reduced IL-22 produc-
tion by 62% (at 1 μg/ml OVAp) as compared with isotype 
control (Fig. 3 C). A similar reduction of IL-22 expression 
was observed with anti–IL-12p40 (64%), suggesting that IL-
23, and not IL-12, is responsible for the majority of IL-22 
production. Collectively, these data demonstrate that IL-23 is 
required for optimal expansion of IL-22–producing cells.
IL-22 is coexpressed with IL-17A and IL-17F in vivo
Our in vitro data demonstrate that IL-22 is coexpressed with 
IL-17A and IL-17F. To examine if this population exists 
in vivo, we performed intracellular cytokine staining on 
draining LN cells harvested from C57BL/6 mice that had 
been immunized with OVA/CFA 7 d earlier. Immunization 
with OVA/CFA increased the expansion of IL-22+ (0.34%), 
IL-17A+ (0.35%), and IL-17F+ (0.43%) cells as compared 
with unimmunized mice (Fig. 4 A). IL-22 was coexpressed 
with IL-17A (44% of IL-17A+ cells were IL-22+) and IL-17F 
(45% of IL-17F+ cells were IL-22+), but not with IFN-γ, 
IL-4, or IL-10 (Fig. 4 B). We also did not observe any coex-
pression of IL-17A or IL-17F with IFN-γ, IL-4, or IL-10 
(not depicted). We did detect considerable, but not com-
plete, coexpression between IL-17A and IL-17F (Fig. 4 C). 
Figure 5.  IL-22 in combination with IL-17A or IL-17F coopera-
tively enhances the expression of antimicrobial peptides. Primary 
human keratinocytes were stimulated with IL-22, IL-17A, or IL-17F indi-
vidually (A) or with pairwise combinations (B) of 200 ng/ml IL-22, 20 ng/ml 
IL-17A, and 20 ng/ml IL-17F for 44 h. Relative amounts of hBD-2, S100A7, 
S100A8, and S100A9 transcript were determined by quantitative 
PCR and normalized to GAPDH. Fold induction was calculated relative 
to untreated keratinocytes (dashed line). Data are representative of at 
least two experiments performed on each of three separate donors. 
Error bars are SD.JEM VOL. 203, October 2, 2006  2277
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These results demonstrate a heterogeneity of IL-17A and 
IL-17F expression within Th17 cells. We further examined 
IL-22 expression in diff  erent populations of IL-17A– and IL-
17F–producing cells and observed the highest IL-22 ex-
pression in IL-17A+IL-17F+ cells (53%; Fig. 4 C). We also 
analyzed the expression of IL-17A and IL-17F in IL-22+ 
cells. The majority (70%) of IL-22+ cells expressed either IL-
17A or IL-17F, with 45% of IL-22+ cells expressing both 
(Fig. 4 D). These in vivo expression profi  les among IL-17A, 
IL-17F, and IL-22 are similar to the expression profi  les 
  generated in vitro with TGF-β, IL-6, IL-1β, TNF-α, and 
IL-23 (Fig. 2 D), suggesting that this in vitro condition is suf-
fi  cient to replicate in vivo Th17 diff  erentiation. Similar   results 
were also observed on days 4 and 10 after immunization (not 
depicted). These data demonstrate that IL-22 is not coex-
pressed with IFN-γ, IL-4, and IL-10 in vivo, but rather with 
IL-17A and IL-17F.
To examine if IL-12 or IL-23 stimulates IL-22 produc-
tion from in vivo–primed T cells, LN cells were restimulated 
in the presence of exogenous IL-12 or IL-23. The addition 
of IL-23 enhanced the production of IL-22 by sevenfold 
compared with OVA alone, whereas IL-12 had no eff  ect 
(Fig. 4 E). These data further demonstrate that IL-23, rather 
than IL-12, is the stimulus for enhancing IL-22 production.
IL-22, IL-17A, and IL-17F cooperatively induce 
antimicrobial peptides
One function of IL-22 is to enhance the expression of anti-
microbial peptides associated with host defense, including 
β-defensin 2 (hBD-2), S100A7, S100A8, and S100A9 (12, 
15). To examine whether IL-17A, IL-17F, and IL-22 can act 
cooperatively to regulate these genes, we treated primary ke-
ratinocytes with individual or paired combinations of these 
cytokines. IL-17A enhanced transcript expression of all four 
antimicrobial peptides (5–70-fold induction at 200 ng/ml; 
Fig. 5 A). IL-22 also induced all four transcripts (two- to 
  fi  vefold at 200 ng/ml), whereas IL-17F (200 ng/ml) induced 
hBD-2 by eightfold, S100A8 by 1.5-fold, and S100A9 by 
twofold, but did not up-regulate S100A7. We then cultured 
keratinocytes with paired cytokine combinations. Treatment 
with IL-22 (200 ng/ml) and IL-17A (20 ng/ml) led to a syn-
ergistic increase of hBD-2 (IL-22, fi  vefold; IL-17A, 70-fold; 
IL-22+IL-17A, 180-fold) and S100A9 (IL-22, twofold; 
IL-17A, fi  vefold; IL-22+IL-17A, 13-fold) and an additive in-
crease of S100A7 and S100A8 expression (Fig. 5 B). Treatment 
with IL-22 (200 ng/ml) and IL-17F (20 ng/ml) also synergis-
tically enhanced hBD-2 (IL-22, fi  vefold; IL-17F, twofold; 
IL-22+IL-17F, 20-fold). Even though S100A7, S100A8, and 
S100A9 were not up- regulated by IL-17F (20 ng/ml) alone, 
IL-17F plus IL-22 enhanced the expression of these three 
peptides by twofold over IL-22 alone. These data demon-
strate that IL-22 can act cooperatively, either synergistically 
or additively, with IL-17A or IL-17F. Keratinocytes treated 
with a combination of IL-17A and IL-17F enhanced S100A8, 
but did not further enhance expression of hBD-2, S100A7, 
or S100A9. The combination of IL-17A and IL-17F resulted 
in less induction of these genes than the combination 
of IL-22 with IL-17A or IL-17F. Expression of receptors for 
IL-22 (IL-22R1) or IL-17 (IL-17RA) were not altered by 
IL-22, IL-17A, or IL-17F (not depicted), suggesting that 
these eff  ects are not related to changes in receptor expression. 
These data demonstrate that IL-22 in combination with 
IL-17A or IL-17F cooperatively enhances the expression of 
antimicrobial peptides.
IL-22 was initially characterized as a Th1 cytokine be-
cause IL-12 treatment of T cells up-regulates IL-22 mRNA 
(17). Here, we show that IL-22 protein is expressed in the 
Th17 lineage at substantially higher amounts than Th1 or 
Th2, revealing a new eff  ector cytokine secreted by Th17 
cells. Despite IL-22 being a Th17 cytokine, the IL-22 locus 
is located  90 kb in proximity to IFN-γ. The distinct ex-
pression pattern of IL-22 and IFN-γ suggests cis-regulatory 
elements exist near these loci that regulate the diff  erentiation 
of Th1 versus Th17 cells. Further analysis of these loci may 
improve our understanding of the elements that control 
T cell diff  erentiation.
Our data also defi  ne a new function for IL-23: the induc-
tion of IL-22 from T cells. Although IL-17A is a critical cy-
tokine induced by IL-23, certain data suggests that IL-17A 
may not account for all the downstream eff  ects of IL-23. For 
example, IL-23p19–defi  cient mice are completely resistant 
to disease in collagen-induced arthritis, whereas IL-17A–
  defi  cient mice remain susceptible, albeit with a signifi  cantly 
reduced incidence and severity (9, 10). Also, IL-23p19–defi  -
cient mice are very susceptible to Citrobacter rodentium infec-
tion despite maintaining wild-type expression of IL-17A (7). 
IL-22 may play a role in these in vivo model systems.
The coexpression of IL-22 with IL-17A and IL-17F 
from T cells and the presence of their receptors on fi  broblast 
and epithelial cells suggest that these cytokines may act to-
gether to regulate local tissue infl  ammation. One mecha-
nism is by the induction of cytokine and chemokine 
expression. Similar to IL-17A and IL-17F, IL-22 induces 
IL-6, CXCL8, and MCP-1 expression by fi  broblast cells 
(1, 13, 14). On colonic myofi  broblasts, IL-22 and IL-17A 
additively enhance expression of CXCL8, IL-6, and LIF, as 
well as activation of transcription factors, further demon-
strating a cooperative signaling relationship between these 
cytokines (14). IL-22, in contrast to IL-17A, did not en-
hance mRNA expression for a variety of chemokines from 
primary keratinocytes (not depicted), suggesting that the 
functions of IL-22 and IL-17A are cell type dependent. We 
have demonstrated that IL-22 can function in synergy with 
IL-17A or IL-17F to enhance keratinocyte expression of 
  antimicrobial peptides. These peptides are known to have  potent 
activity against bacteria such as K. pneumoniae, supporting 
the idea that Th17 cells may have evolved to combat extra-
cellular pathogens (11, 18). Although these data point to 
a function for IL-22 in infl  ammation, the essential role of 
IL-22 and its interplay with IL-17A and IL-17F in vivo are 
not well understood. The coexpression of IL-22 with IL-
17A and IL-17F adds a new layer of complexity and prompts 2278  IL-22 IS A TH17 CYTOKINE | Liang et al. 
new directions for future investigation on the development 
and functions of the Th17 lineage.
MATERIALS AND METHODS
Antibodies and recombinant cytokines. Murine IL-4, IL-6, IL-12, 
IL-23, TNF-α, and GM-CSF and human IL-17A were purchased from 
R&D Systems. Murine IL-2 and human TGF-β were purchased from 
Sigma-Aldrich. Murine IL-1β was obtained from Bender MedSystems. 
IL-22 and IL-17F cytokines were prepared by previously described methods 
(19). Antibodies to IFN-γ (XMG1.2), IL-4 (BVD4-1D11), IL-17A (TC11-
18H10), IL-10 (JES5-16E3), and CD4 (RM4-5) were purchased from BD 
Biosciences. Anti–IL-12p40 (C17.8) and anti–IL-23R (258010) were ob-
tained from R&D Systems. Anti-DO11 antibody (KJ126) was purchased 
from Caltag Laboratories. Antibodies to murine IL-22 (Ab-01, Ab-02, 
and Ab-03) and murine IL-17F (RK015-1) were generated by methods as 
described previously (19).
Mice. BALB/cByJ, C57BL/6, and C.Cg-Tg(DO11.10)10Dlo TCR trans-
genic mice were purchased from The Jackson Laboratory. All mice 
were used between 6 to 10 wk of age. Mice were immunized subcutane-
ously in the fl  anks with 100 μg OVA (Sigma-Aldrich) emulsifi  ed in CFA 
(Sigma-  Aldrich). 7 d later, inguinal LNs were harvested. All mice were 
maintained in strict accordance with Wyeth Research Institutional Animal 
Care and Use Committee regulations.
In vitro T cell activation. Naive (CD62LhiCD4+) T cells were purifi  ed 
from the spleens of DO11 mice by CD4 negative selection followed by 
CD62L positive selection according to the manufacturer’s directions (Miltenyi 
Biotec). In a 24-well plate, 2 × 105 DO11 T cells were cultured with 4 × 106 
irradiated BALB/cByJ splenocytes (3,300 rad) and 1 μg/ml OVA323–339 pep-
tide (OVAp; New England Peptide). Recombinant cytokines and neutraliz-
ing antibodies were used at the following concentrations: 10 ng/ml IL-12, 
10 ng/ml IL-4, 1 ng/ml TGF-β, 20 ng/ml IL-6, 10 ng/ml IL-1β, 10 ng/ml 
TNF-α, 10 ng/ml IL-23, 10 μg/ml anti–IFN-γ, and 10 μg/ml anti–IL-4. In 
some cases, cells were labeled with CFSE (Invitrogen) according to the manu-
facturer’s directions. For restimulation cultures, cells were harvested on day 7 
of primary stimulation, washed extensively, and rested overnight. 2 × 105 
DO11 T cells were restimulated with 4 × 106 irradiated splenocytes, 5 ng/ml 
IL-2, and various conditions as indicated. Conditioned media was collected 
on day 5 for optimal cytokine accumulation. For generation of DCs, BM cells 
were cultured with 10 ng/ml GM-CSF and 1 ng/ml IL-4 for 7 d. After puri-
fi  cation by CD11c positive selection (Miltenyi Biotec), DCs were matured for 
24 h with 1 μg/ml LPS (Escherichia Coli serotype 0111-B4; Sigma-Aldrich). 
DCs were then washed, and 104 DCs were cultured with 2 × 104 purifi  ed 
  naive DO11 T cells, OVAp, and 10 μg/ml anti–IL-12p40, anti–IL-23R, 
or relevant isotype controls in a 96-well plate. For ex vivo restimulations, 
4 × 105 inguinal LN cells were restimulated with 200 μg/ml OVA alone or 
with 10 ng/ml exogenous IL-12 or IL-23. All lymphocyte cultures were 
grown in RPMI 1640 supplemented with 10% FBS, 2 mM L-glutamine, 
5 mM Hepes, 100 U/ml Pen-Strep, and 2.5 μM β-mercaptoethanol.
Quantitation of cytokine transcripts. Naive DO11 T cells were diff  eren-
tiated to Th1, Th2, and Th17 as described above. On day 7, CD4+ T cells 
were purifi  ed by positive selection (Miltenyi Biotec) and rested overnight. 
Cells were then restimulated with 50 ng/ml PMA (Sigma-Aldrich), 1 μg/ml 
ionomycin (Sigma-Aldrich), and with the following conditions: Th1 cells 
(IL-12, anti–IL-4), Th2 cells (IL-4, anti–IFN-γ), or Th17 (IL-23, anti–IFN-γ, 
anti–IL-4) for 6 h before RNA was isolated. Quantitative PCR for cytokine 
transcripts was performed using SYBR Green Platinum Taq (Invitrogen) and 
prequalifi  ed primers (QIAGEN). The ∆∆Ct method was used to normalize 
transcript to HPRT and to calculate fold induction relative to purifi  ed, unac-
tivated naive DO11 T cells.
Intracellular cytokine staining. Cells were restimulated with 50 ng/ml 
PMA, 1 μg/ml ionomycin, and GolgiPlug (BD Biosciences) for 6 h. Cells 
were fi   rst stained for surface antigens and then treated with Cytofi  x/ 
Cytoperm (BD Biosciences) according to the manufacturer’s directions. 
  Intracellular cytokine staining was performed using PE-conjugated anti-
bodies to IFN-γ, IL-4, IL-10, and IL-17A as described above. Anti–IL-22 
(Ab-02) was labeled with Alexa 647 (Invitrogen) and anti–IL-17F (RK015-1) 
was labeled with FITC (Pierce Biotechnologies) according to the manu-
facturer’s directions.
Quantitation of cytokine concentrations. Antibody pairs (coating, 
  detection) were used to detect IFN-γ (AN-18, R4-6A2; eBioscience), 
IL-17A (MAB721, BAF421; R&D Systems), and IL-22 (Ab-01, biotinylated 
Ab-03) by standard sandwich ELISA.
Keratinocyte cultures. Primary human keratinocytes (ScienCell) were 
cultured in keratinocyte medium (ScienCell) on human fi  bronectin-coated 
plates (BD Biosciences). Cells were passaged at 80% confl   uency and all 
  experiments were done between passages 2 and 4. For evaluation of cytokine 
eff  ects, 15,000 cells were seeded into a 24-well plate and allowed to adhere 
for 48 h. Cells were then treated with human IL-22, IL-17A, and IL-17F 
for 44 h. RNA was purifi  ed and quantitative PCR was performed using 
Taqman Real-Time PCR and prequalifi  ed primer probes (Applied Biosystems). 
Fold induction was calculated as described above.
Online supplemental material. Fig. S1 shows the mRNA expression 
of non–T cell–derived cytokines by Th1, Th2, and Th17 diff  erentiated 
cells. Fig. S2 shows the eff  ects of IL-22 on naive and diff  erentiated T cells. 
Fig. S3 shows the role of endogenous TGF-β on IL-22 expression induced 
by IL-6, IL-1β, and TNF-α. Figs. S1–S3 are available at http://www.jem.
org/cgi/content/full/jem.20061308/DC1.
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